Physical Confirmation and Comparative Genomics of the Rat Mammary carcinoma susceptibility 3 Quantitative Trait Locus

Saasha Le,* Zachary C. Martin,* and David J. Samuelson*,†,‡,*
*Department of Biochemistry and Molecular Genetics, †James Graham Brown Cancer Center, and ‡Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, University of Louisville School of Medicine, HSC-A Bldg., Room 606, 319 Abraham Flexner Way, Louisville, KY 40292. E-mail: david.samuelson@louisville.edu

ABSTRACT Human breast and rat mammary cancer susceptibility are complex phenotypes where complete sets of risk associated loci remain to be identified for both species. We tested multiple congenic rat strains to physically confirm and positionally map rat Mammary carcinoma susceptibility 3 (Mcs3)—a mammary cancer resistance allele previously predicted at Rattus norvegicus chromosome 1 (RNO1). The mammary cancer susceptible Wistar Furth (WF) strain was the recipient, and the mammary cancer resistant Copenhagen (Cop) strain was the RNO1-segment donor for congenics. Inbred WF females averaged 6.3 carcinogen-induced mammary carcinomas per rat. Two WF.Cop congenic strains averaged 2.8 and 3.4 mammary carcinomas per rat, which confirmed Mcs3 as an independently acting allele. Two other WF.Cop congenic strains averaged 6.6 and 8.1 mammary carcinomas per rat, and, thus, did not contain Mcs3. Rat Mcs3 was delimited to 27.8 Mb of RNO1 from rs8149408 to rs105131702 (RNO1:143700228-171517317 of RGSC 6.0/m6). Human genetic variants with p values for association to breast cancer risk below $10^{-7}$ had not been reported for Mcs3 orthologous loci; however, human variants located in Mcs3-orthologous regions with potential association to risk ($10^{-7} < p < 10^{-2}$) were listed in some population-based studies. Further, rat Mcs3 contains sequence orthologous to human 11q13/14—a region frequently amplified in female breast cancer. We conclude that Mcs3 is an independently acting mammary carcinoma resistance allele. Human population-based, genome-targeted association studies interrogating Mcs3 orthologous loci may yield novel breast cancer risk associated variants and genes.

Excluding skin cancer, breast cancer is the most commonly diagnosed cancer among women in the United States, accounting for 29% of cancers diagnosed, and 14% of cancer-related deaths in females (Siegel et al. 2016). The current population-based lifetime-risk of a woman being diagnosed with breast cancer is 12–13% (Siegel et al. 2016). Breast cancer susceptibility is a complex trait controlled by genetic, epigenetic, and environmental factors. The genetic component of breast cancer susceptibility is comprised of a spectrum of high, moderate, and low penetrance risk associated mutations and variants (Pharoah et al. 2002). Genetic linkage analyses and genome-wide association studies (GWAS) have enabled the identification of several risk alleles, but a majority of susceptibility loci remain unidentified (Smith et al. 2006; Ioannidis et al. 2010; Mavaddat et al. 2010; Economopoulou et al. 2015). Furthermore, GWAS have yielded many potentially associated variants. These are polymorphisms with p values for association above a stringent genome-wide significance threshold level of $1 \times 10^{-7}$, which is commonly used to avoid false-positive associations (Thomas et al. 2005). Comparative genomics approaches that integrate relevant QTL of experimental organisms and human loci, containing potentially associated variants, may be useful to identify additional risk associated alleles. To serve this approach, mammary cancer susceptibility QTL identified in experimental organisms must be mapped to conserved...
Laboratory rats (Rattus norvegicus) provide a good experimental model of female breast cancer, as rat mammary carcinomas are similar to human breast carcinomas with respect to histopathology and hormone responsiveness (Gould 1995). Evidence suggests that both rat mammary and human breast carcinomas originate from mammary ductal cells (Russo et al. 1983). Inbred rat strains that differ in susceptibility to 7,12-dimethylbenz[a]anthracene (DMBA)-, N-methyl-N-nitrosourea (NMU)-, or estrogen-induced mammary carcinogenesis have been used to predict locations of Mammary carcinoma susceptibility (Mcs) and Estrogen-induced mammary cancer (Emca) loci (Hsu et al. 1994; Shepel et al. 1998; Lan et al. 2001; Gould et al. 2004; Quan et al. 2006; Schaffer et al. 2006; Ren et al. 2013). Linkage analyses using crosses between the DMBA-induced mammary carcinoma susceptible Wistar-Furth (WF) and resistant Copenhagen (Cop) strains resulted in four predicted Mcs QTL named Mcs1, Mcs2, Mcs3, and Mcs4 (Hsu et al. 1994; Shepel et al. 1998). Resistance-associated QTL, Mcs1 and Mcs2, have been physically confirmed (Haag et al. 2003; Sanders et al. 2011). In this article, we report our congenic strain results that physically confirm rat Mcs3, and delimit this Cop resistance QTL to a 27.8 Mb segment of rat chromosome 1 (RNO1).

MATERIALS AND METHODS

Congenic breeding and genotyping
Congenic lines were made by adapting previously described methods to RNO1 (Samuelson et al. 2003). Briefly, rats with selected Cop RNO1 segments from the predicted Mcs3 QTL were introgressed into a WF/NHsd genetic background by successive backcrossing to the WF strain. Congenic rat lines were maintained in an Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)-approved facility on a 12-hr light/dark cycle, and provided LabDiet 5001 Rodent Diet (PMI Nutrition International) and water ad libitum. All animal protocols were approved by the University of Louisville Animal Care and Use Committee. Sequence information and locations of genetic markers defining the ends of COP alleles in each congenic line A, D, E, and G are available at the UCSC Genome Browser (www.genome.ucsc.edu), the Rat Genome Database (http://rgd.mcw.edu/), or Supplemental Material, Table S1. Animals were genotyped as described in Samuelson et al. (2003). Briefly, tail clips were used for DNA extraction and genotyping by either gel electrophoresis or Sanger sequencing of PCR products. Informative genetic markers at respective congenic ends, and at 10 Mb intervals between ends, were used to determine genotypes. For microsatellite markers, each fast-PCR product was denatured of 95° for 10 sec, followed by 40 cycles of 94° for 0 sec and 63° for 8 sec, and an extension at 72° for 30 sec on an Applied Biosystems Veriti Fast Thermal Cycler. Amplified genomic DNA was run on a 3% high-resolution agarose gel. After electrophoresis, gels were stained in SYBR Gold and scanned using a Typhoon imager. Visible gel-bands of the appropriate size were analyzed along with DNA from homozygous Cop and WF, and (WF × Cop)F1 (heterozygous) rats. In regions where informative microsatellite markers were limiting, Primer3 was used to design primers to PCR amplify genomic regions containing potentially WF/Cop informative single nucleotide variants (SNVs), identified using the SNPloftery function available at the Rat Genome Database. Genomic DNA was extracted from spleen tissue, and PCR amplified. These reactions were cleaned using Promega Wizard SV Gel and PCR clean-up system. Samples were sequenced by the University of Louisville, Center for Genetics and Molecular Medicine, sequencing core using an ABI PRISM 7700 Sequence Detection System. Primer sequences that define the ends of Mcs3 congenic lines A and E can be found in Table S2.

Phenotyping
Female WF.Cop congenic and WF/NHsd (Envigo) rats were gavaged with a single oral dose of DMBA (65 mg DMBA/kg body mass) in
Table 1: Mammary carcinoma multiplicity phenotypes of WF.Cop RNO1 congenic and WF/NHsd females

| Strain    | Genetic Markers Spanning Cop RNO1 Maximal Segment | Phenotype Mean ± SD | N   | p-Value* |
|-----------|--------------------------------------------------|---------------------|-----|----------|
| A         | rs105079134 to rs105137102                       | 3.4 ± 2.2           | 30  | 0.019    |
| D         | D1Rat320 to D1Rat65                             | 2.8 ± 2.3           | 19  | 0.015    |
| E         | rs105079134 to rs107402736                      | 6.6 ± 3.4           | 25  | 0.935    |
| G         | rs105079134 to D1Rat321                         | 8.1 ± 3.4           | 29  | 0.334    |
| WF/NHsd   | NA                                               | 6.3 ± 3.8           | 12  | —        |

WF, Wistar Furth; Cop, Copenhagen; SD, standard deviation; NA, not applicable.

* p-values from Mann-Whitney post hoc tests comparing each congenic line phenotype to a susceptible WF/NHsd phenotype following a statistically significant Kruskal-Wallis test with p-value < 0.0001.

Comparative genomics

Human orthologous regions and transcripts mapping to the delimited rat Mcs3 and human orthologous loci were identified using the UCSC Genome Browser. The R. norvegicus reference genome sequence version RGSC 6.0/rn6 and Homo sapiens version GRCh38/hg38 were used. Breast cancer associated genes were identified by searching NCBI/PubMed using the respective Mcs3-nominated gene name and breast cancer as search terms. Databases at NHGRI-EBI (Welter et al. 2014) and GWAS Central (Beck et al. 2014) were searched for variants located in Mcs3 orthologous regions that had p values of 1 × 10^-3 or less for association to breast cancer.

Statistical analysis

Mammary carcinoma multiplicity data were analyzed by comparing congenic strain phenotypes to a susceptible WF/NHsd phenotype. First, mammary carcinoma multiplicity phenotypes for all lines were compared using the Kruskal-Wallis nonparametric test to protect for multiple comparisons. Following a significant Kruskal-Wallis test, which was p < 0.0001, select group comparisons were made by two-tailed Mann-Whitney nonparametric tests corrected for ties; p values ≤ 0.05 were considered statistically significant.

Data availability

Strain WF.Cop D is available upon request. Table S1 contains sequence and location information for primers to amplify microsatellite markers on RNO1. Table S2 contains sequence and location information for primers to amplify RNO1 SNV containing sequences. File S1 contains a list of Mcs3-nominated breast cancer susceptibility candidate genes.

Table 2: Minimum-number or names of genes at human loci containing rat Mcs3 orthologous sequence

| Human Locus | Position* | Gene Transcripts (Minimum Number or Name) |
|-------------|-----------|------------------------------------------|
| 15q25.2     | 15:83134545–84130720 | 6, 5, 5 |
| 15q25.1–15q25.2 | 15:80005820–82285404 | 22, 13, 13 |
| 11q13.4–11q13.5, 11q14.1–11q14.3 | 11:71915764–89617253 | 142, 103, 87 |
| 11p15.4     | 11:3609839–7196087 | 113, 186, 90 |
| Xq28        | X:154888349–154888061 | F8A1, F8a1 |
| 10q23.33    | 10:94762624–94853260 | CYP2C19, Cyp2c6v1 |
| 11p11.12    | 11:4914635–49206870 | FOLH1, Foh1 |
| 2p16.3      | 2:51696250–51787033 | LOC730100, LOC730100 |
| Total       | 287       | 310, 198 |

Rat Mcs3 from SNVs rs8149408 to rs105137102 or RNO1:143700228–171517317 (RGSC 6.0/rn6).

RESULTS

Physical confirmation and positional mapping of Mcs3 With WF.Cop congenics

The Mcs3 QTL was predicted to exist on RNO1 by the laboratory of M. N. Gould in a previous study (Shepel et al. 1998). Figure 1 is a map of WF.Cop congenic strains used in the present study to physically confirm and positionally map the location of Mcs3. Table 1 contains DMBA-induced mammary carcinoma susceptibility phenotypes (mean ± SD mammary carcinomas per rat) of the congenic lines depicted in Figure 1. Congenic lines A (n = 30) and D (n = 19) developed 3.4 ± 2.2 and 2.8 ± 2.3 mammary tumors per rat, respectively. Mammary cancer susceptible WF females (n = 12) developed 6.3 ± 3.8 DMBA-induced mammary carcinomas per rat. Females from lines A and D developed significantly less mammary tumors per rat compared to susceptible WF control females (p-values = 0.019 and 0.015, respectively). Reduced susceptibility lines A and D contained partially overlapping segments of Cop RNO1, and were not different from each other with respect to DMBA-induced tumor multiplicity (p-value = 0.198). This suggests that these congenic lines likely contain the same QTL. Thus, the reduced susceptibility phenotypes of both lines, A and D, physically confirm the Mcs3 locus.

Congenic lines E (n = 25) and G (n = 29) developed 6.6 ± 3.4 and 8.1 ± 3.4 mammary tumors per rat, respectively. Neither line was significantly different in tumor multiplicity compared to susceptible WF rats (p-values = 0.935 and 0.334, respectively). Thus, neither line E nor line G contains an independently acting mammary carcinoma susceptibility QTL with an effect on the WF susceptibility phenotype.

The region of overlap between Cop RNO1 segments that indicated a presence of at least one independently acting Mcs3 allele (lines A and D) in combination with nonoverlap between these segments and the Cop RNO1 segment contained in line E, which did not indicate the presence of an independently acting Cop allele, was used to delimit the
**Table 3** Rat Mcs3-nominated human genes and amplified region correlated with breast cancer development

| ID     | Name                              | Locus       | RefSeq on Function                                                   | Reference       |
|--------|-----------------------------------|-------------|---------------------------------------------------------------------|-----------------|
| Genes  |                                   |             |                                                                     |                 |
| ILK    | Integrin-linked kinase            | 11p15.4     | Serine/threonine kinase that regulates integrin-mediated signaling   | Yang et al. (2013) |
| IL18BP | Interleukin 18 binding protein    | 11q13.4     | Inhibitor of proinflammatory cytokine IL18                         | Yang et al. (2015) |
| EMSY   | EMSY, BRCA2 interacting transcriptional repressor | 11q13.5 | Repression of BRCA2-mediated DNA repair                             | Hughes-Davies et al. (2003), Majdij et al. (2014) |
| PAK1   | p21 (RAC1) activated kinase 1     | 11q13.5–q14.1 | Serine/threonine kinase that regulates cell motility and morphology | Adam et al. (2000), Wang et al. (2005), Bostner et al. (2007), Ren et al. (2014) |
| RSF1   | Remodeling and spacing factor 1   | 11q14.1     | Histone chaperone involved in RSF chromatin-remodeling complex      |                 |
| GAB2   | GRB2 associated binding protein 2  | 11q14.1     | Adapter protein involved in signal transduction with a known role in PI3K activation | Bocanegra et al. (2010) |
| CYP2C19| Cytochrome P450 family 2 subfamily C member 19 | 10q23.33 | Monoxygenase involved in xenobiotic and estrogen metabolism         | Justenhoven et al. (2009), Sangrajrang et al. (2009), Gan et al. (2011) |
| Amplified region | 11q13/14 |             | Amplified in a subset of breast cancers that are typically ER+ and have a poor prognosis | Tsuda et al. (1989) |

Mcs3 QTL interval (Figure 1). Congenic Mcs3-resistance-associated lines A and D overlapped each other minimally from markers D1Rat321 to rs105307119, and maximally from D1Rat320 to rs105131702. Susceptible line E minimally overlapped resistance-associated line A from rs105409983 to rs8149408 and resistance-associated line D from D1Rat320 to rs8149408. Considering the phenotypes and relevant regions of overlap and nonoverlap of lines A, D, and E, the Mcs3 QTL was delimited to a 27.8 Mb region of RNO1 that spans from SNVs rs8149408 to rs105131702. Respectively, these SNVs physically mapped to RNO1 base positions 143,700,228 and 171,517,317 of the rat reference genome build RGSC 6.0/rn6.

Results of the original QTL scan predicted two LOD score peaks on RNO1 at markers D1Mit11 and D1Wox6 (Shepel et al. 1998). These peak markers are denoted with asterisks in Figure 1. Congenic line E had the Cop genotype at both peak markers, but did not have an Mcs3-associated resistance phenotype, as would be predicted based on the original QTL scan. The phenotype of congenic line E, which was derived from line E and contained the Cop allele at D1Mit11 and the WF allele at D1Wox6, was measured to determine if epistatic QTL might be responsible for the susceptibility phenotype of line E. The susceptibility phenotypes of lines E and G were not significantly different when compared to each other (p-value = 0.182). Thus, we did not uncover evidence of an epistatic interaction to potentially explain the susceptibility phenotype of line E.

**Human orthologous regions to the rat Mcs3 QTL**

The delimited rat Mcs3 QTL from rs8149408 to rs105131702 of RNO1 was found to align to four syntenic regions of human chromosomes 11 and 15 and four other regions of the human genome that contained a single gene (Table 2). The UCSC genome browser (https://genome.ucsc.edu) was used to identify known genes at rat Mcs3 and orthologous human loci (Kent et al. 2002; Karolchik et al. 2004). These genes are listed in File S1. There were 310 rat and 287 human genes annotated in the respective genomic intervals. At least 198 of these genes were in common or orthologous between these species.

Public databases, namely the NHGRI-EBI catalog (https://www.ebi.ac.uk/gwas) (Welter et al. 2014), GWAS Central (www.gwascentral.org) (Beck et al. 2014), NCBI PubMed (https://www.ncbi.nlm.nih.gov/pubmed), and the Cancer Portal of Rat Genome Database (RGD) (https://rgd.mcw.edu), were searched to identify genes and genetic variation at Mcs3 orthologous human genome regions that have been associated with breast carcinoma susceptibility and development. Table 3 contains a list of female breast cancer associated genes and amplified regions that have Mcs3-nominated rat orthologs. Rat Mcs3 was found to contain sequence orthologous to human 11q13/14, which contains multiple genes and is amplified in a subset of female breast carcinomas with poor prognosis (Tsuda et al. 1989). In addition to a functional correlation with breast cancer development, studies reporting genetic associations of CYP2C19 variants with breast cancer susceptibility have been published (Justenhoven et al. 2009; Sangrajrang et al. 2009; Gan et al. 2011).

Genome-wide significant associations (p values < 10^-7) between human genetic variants located in Mcs3-orthologous multigene regions and female breast cancer risk have not been reported, but potentially associated variants with p values < 10^-3 have been reported (Table 4).

**DISCUSSION**

Rat Mcs3 was physically confirmed and delimited to a 27.8 Mb segment of rat chromosome 1. Rat Mcs3 is the last of the known Cop mammary carcinoma resistance-associated QTL (Mcs1-3) to be physically confirmed. In their linkage analysis predicting the Mcs3 QTL, Gould’s group reported that Mcs3 heterozygous females had, on average, a 42% reduction in mammary carcinoma multiplicity compared to the WF phenotype, and females homozygous for the Mcs3 Cop allele had an 84% reduction in mammary tumor number (Shepel et al. 1998). Thus, they appropriately concluded that there was no dominance effect at the Mcs3 QTL. While we did not test heterozygous females in our study, we observed that the Mcs3 Cop allele reduced the mammary carcinoma susceptibility phenotype of the highly susceptible WF strain from 46 to 65% when homozygous. The discrepancy between homozygous genotypes in these two studies may be due to effects of Cop resistance alleles at other Mcs QTL present in the linkage analysis study, as the F2 females in that study were not required to be WF homozygous at Mcs1 or Mcs2 resistance-associated QTL. Another possibility is that
Mcs3 contains multiple independent QTL, and at least one of these was not contained in the congenic strains tested for our study. The 27.8 Mb region of RNO1 from SNVs rs81194908 to rs105131702 is the segment most likely to contain Mcs3; however, it is possible that Mcs3 is more complex. For example, an interaction between one or more elements in the delimited region and elements outside of this region could be required to confer the Mcs3-associated phenotype. The delimited Mcs3 segment is distal to both D1Mit11 and D1Wox6, the markers with peak LOD scores from the original QTL scan, but within the predicted Mcs3 QTL interval (Shepel et al. 1998). This is not the first time a rat Mcs locus has been mapped to a genomic segment that did not contain a peak marker of the original QTL scan. For example, neither Mcs1D nor Mcs1c QTL contain the peak LOD marker of the predicted Mcs1 QTL (Haag et al. 2003; denDekker et al. 2012). The Mcs3 QTL, as delimited here, overlaps the distal third of mouse Mammary tumor susceptibility modifier 1 (Mtsm1) (Koch et al. 2007). Interestingly, the mouse Mtsm1 segment overlapping rat Mcs3 does not contain the peak LOD score marker defining the Mtsm1 QTL. Furthermore, it is worth noting that Mcs3 had one of the lowest LOD scores of Mcs QTL identified in linkage analyses using WF females as the susceptible strain (Shepel et al. 1998; Lan et al. 2001). Thus, interval mapping effectively predicted rat Mcs QTL, and, as expected, a wide genomic region of interrogation was required in congruent studies to pinpoint the location of each QTL for fine mapping.

Most importantly, this work provides information that is translatable to the genetic component of human breast cancer by using a versatile experimental organism that is highly relevant to female breast cancer. Different segments of the rat Mcs3 locus align to four multigene human syntenic regions on chromosomes 11 and 15, and four single-gene loci at Xq28, 2p16.3, 10p23.33, and 11p11.12. The rat Mcs3 locus contains 310 annotated genes, and the orthologous human regions contain 287 annotated genes. To reduce the number of Mcs3-nominated candidate susceptibility genes, it will be necessary to fine-map the Mcs3 locus. However, the human orthologous regions to rat Mcs3 could be targeted for deep genetic analysis to determine if these regions contain risk-associated variants. In support of this direction, population-based genetic association studies have identified potentially associated variants at Mcs3 orthologous loci 2p16.3, 11p15.4, 11q14.1, 11q14.2, and 15q25.2 (Easton et al. 2007; Hunter et al. 2007; Kibriya et al. 2009). This provides strong rationale for additional human studies to identify risk associated variants at these loci. Human genome targeted association studies require considerable resources, as a high density of variants and a large sample size are required to properly test each targeted locus. Guidance from both rat genomics and previous human genetic studies stands to increase the likelihood of finding positive associations. Thus, these human loci are excellent candidates for further genetic analyses to test a high density of variants for association to risk.

Discussion of the entire list of genes located within the Mcs3 QTL, as currently defined, is not practical; however, it is notable that some Mcs3-nominated candidate susceptibility genes have known or suggested roles in breast cancer progression, diagnosis, or prognosis. This list includes p21 (RAC1) activated kinase 1 (PAK1), EMSY, BRCA2 interacting transcriptional repressor (EMSY), remodeling and spacing factor 1 (RSF1), GRB2-associated binding protein 2 (GAB2), integrin-linked protein kinase (ILK), interleukin-18-binding protein (IL18BP), and cytochrome P450 family 2 subfamily C member 19 (CYP2C19).

The EMSY, PAK1, RSF1, and GAB2 genes are located within the 11q13/14 breast cancer amplicon. Interestingly, the breast cancer oncogene cyclin D1 (CCND1), which is also located within the 11q13/14 amplicon, is not contained within the rat Mcs3 delimited region. The EMSY gene encodes a BRCA2 binding partner that silences a potential transcription activation domain of BRCA2, thereby repressing BRCA2-mediated DNA repair (Hughes-Davies et al. 2003; Moelans et al. 2010). Amplification of EMSY has been reported in 13% of breast cancers, and is associated with poor survival, especially in node negative breast cancer (Hughes-Davies et al. 2003). A recent study reported a significant positive association between EMSY expression and lymph node metastasis, as well as a larger tumor size (Madjd et al. 2014). The PAK1 gene product has many roles in cancer, including breast cancer progression, development and maintenance of a metastatic phenotype of breast cancer cells, and a predictor of recurrence and tamoxifen resistance in postmenopausal breast cancer (Adam et al. 2000; Bostner et al. 2007; Kumar and Li 2016). Ectopic expression of activated PAK1 has been shown to induce mouse mammary tumors (Wang et al. 2005). High Rsf-1 expression is associated with breast cancer subtype and poor prognosis (Ren et al. 2014). Amplification of GAB2, independent of CCND1, has been observed in breast carcinoma samples (Daly et al. 2002; Bocanegra et al. 2010).

A direct interaction between PAK1 and ILK proteins has been identified. The activity of ILK is regulated by PAK1 phosphorylation (Acconcia et al. 2007). Higher transcript levels of ILK have been found in human breast cancer tissue compared to adjacent nondiseased breast tissue (Yang et al. 2013). In the same study, breast cancer patients with more intense immunostaining for ILK had lower 5-yr survival than patients with low ILK levels (Yang et al. 2013).
Interleukin-18-binding protein (IL18BP) regulates the activity of IL-18, which has been shown to be higher in breast carcinoma tissue compared to tissue from patients with benign breast disease (Srabovac et al. 2011). Another study suggests that IL-18 enhances breast cancer cell migration (Yang et al. 2015). Due to a potential role of IL-18 in cancer progression and metastasis, an IL18BP-Fc has been developed to antagonize the effects of IL-18 (Cao et al. 2008).

Because of an established role in estrogen metabolism, CYP2C19 variants have been tested for association with breast cancer risk. There is evidence that the CYP2C19*3 variant may be associated with breast cancer risk in Chinese Han women (Gan et al. 2011). Neither the CYP2C19*17 variant, which results in a rapid metabolizer phenotype, nor the CYP2C19*2 variant were associated with breast cancer risk in population-based studies of women of European descent; however, CYP2C19*17 was associated with decreased risk in women using hormone replacement therapy for >10 yr (Justenhoven et al. 2009, 2012; MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk 2010). In a study of cancer recurrence in ER+ postmenopausal breast cancer cases, it was concluded that patients with a CYP2C19-2 allele may benefit more from tamoxifen therapy (Beelen et al. 2013).

In summary, rat Mcs3 is an independently acting QTL located in a 27.8 Mb region on RNO1 between rs8149408 and rs10513702. Additional congenic studies and other genomic approaches will be necessary to reduce the Mcs3-nominated candidate susceptibility gene list and determine mechanisms of Mcs3-associated reduced susceptibility to mammary carcinomas. While an overwhelming list of Mcs3-nominated breast cancer susceptibility candidate genes was identified, a manageable number of orthologous human syntenic regions were found to warrant deeper analysis of these loci in human population-based genetic association studies. The fact that some of these regions contain variants potentially associated with breast cancer risk further supports the need to ultrafine-map these loci to determine if true positive associations to susceptibility exist.

ACKNOWLEDGMENTS

The authors thank Jennifer Sanders, Huy T. Le, and Aaron Puckett for technical assistance. This work was supported by the National Institutes of Health grant R01CA137052, the University of Louisville, School of Medicine, Department of Biochemistry and Molecular Genetics, and the University of Louisville, School of Medicine Research Office.

LITERATURE CITED

Acconia, F. C. J. Barnes, R. R. Singh, A. H. Talukder, and R. Kumar, 2007 Phosphorylation-dependent regulation of nuclear localization and functions of integrin-linked kinase. Proc. Natl. Acad. Sci. USA 104: 6782–6787.

Adam, L., R. Vadlamudi, M. Mandal, J. Chernoff, and R. Kumar, 2000 Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J. Biol. Chem. 275: 12041–12050.

Beck, T., R. K. Hastings, S. Gollapudi, R. C. Free, and A. J. Brookes, 2014 GWAS Central: a comprehensive resource for the comparison and interrogation of genome-wide association studies. Eur. J. Hum. Genet. 22: 949–952.

Beelen, K., M. Opdam, T. M. Severson, R. H. Koornstra, A. D. Vincent et al., 2013 CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Res. Treat. 139: 649–655.

Bocanegra, M., A. Bergamaschi, Y. H. Kim, M. A. Miller, A. B. Rajput et al., 2010 Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 29: 774–779.

Bostner, J., M. A. Waltersson, T. Forndern, L. Skoog, B. Nordenskjöld et al., 2007 Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26: 6997–7005.

Cao, Q., W. Cai, G. Niu, L. He, and X. Chen, 2008 Multimodality imaging of IL-18-binding protein-Fc therapy of experimental lung metastasis. Clin. Cancer Res. 14: 6137–6145.

Daly, R. J., H. Gu, J. Parmar, S. Malaney, R. J. Lyons et al., 2002 The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene 21: 5175–5181.

denDekker, A. D., X. Xu, M. D. Vaughan, A. H. Puckett, L. L. Gardner et al., 2012 Rat Mcs1b is concordant to the genome-wide association-identified breast cancer risk locus at human 5q11.2 and MIER3 is a candidate cancer susceptibility gene. Cancer Res. 72: 6002–6012.

Easton, D. F., K. A. Pooley, A. M. Dunning, D. P. Pharoah, D. Thompson et al., 2007 Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087–1093.

Economopoulos, P., G. Dimitriadis, and A. Psychris, 2015 Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat. Rev. 41: 1–8.

Gan, C. Q., X. Y. Wang, Y. D. Cao, W. X. Ye, H. Liu et al., 2011 Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women. Genet. Mol. Res. 10: 3514–3519.

Gould, K. A., M. Tochacek, B. S. Schaffer, T. M. Reindl, C. R. Murrin et al., 2004 Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics 168: 2113–2125.

Gould, M. N., 1995 Rodent models for the study of etiology, prevention and treatment of breast cancer. Semin. Cancer Biol. 6: 147–152.

Haag, J. D., L. A. Shepel, B. A. Kolman, D. M. Monson, M. E. Benton et al., 2003 Congenic rats reveal three independent Copenhagen alleles within the Mcs1 quantitative trait locus that confer resistance to mammary cancer. Cancer Res. 63: 5808–5812.

Hsu, L. C., W. S. Kennan, L. A. Shepel, H. J. Jacob, C. Szpirer et al., 1994 Genetic identification of Mcs-1, a rat mammary carcinoma suppressor gene. Cancer Res. 54: 2765–2770.

Hughes-Davies, L., D. Huntsman, M. Ruas, F. Fuku, J. Bye et al., 2003 EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115: 523–535.

Hunter, D. J., P. Kraft, K. B. Jacobs, D. G. Cox, M. Yeager et al., 2007 A genome-wide association study identifies alleles in FGF2R associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39: 870–874.

Ioannidis, J. P., P. Castaldi, and E. Evangelou, 2010 A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. J. Natl. Cancer Inst. 102: 846–858.

Justenhoven, C., U. Hamann, C. B. Pierl, C. Baisch, V. Harth et al., 2009 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res. Treat. 115: 391–396.

Justenhoven, C., O. Obaze, S. Winter, F. J. Couch, J. E. Olson et al., 2012 The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. Breast Cancer Res. Treat. 131: 347–350.

Karolchik, D., A. S. Hinrichs, T. S. Furey, K. M. Roskin, C. W. Sugnet et al., 2004 The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 32: D493–D496.

Kent, W. J., C. W. Sugnet, T. S. Furey, K. M. Roskin, T. H. Pringle et al., 2002 The human genome browser at UCSC. Genome Res. 12: 996–1006.

Kibiryi, M. G., F. Jasmine, M. Argos, I. L. Andrulis, E. M. John et al., 2009 A pilot genome-wide association study of early-onset breast cancer. Breast Cancer Res. Treat. 114: 463–477.

Koch, J. G., X. Gu, Y. Han, A. K. El-Naggar, M. V. Olson et al., 2007 Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm. Genome 18: 300–309.

Kumar, R., and D. Q. Li, 2016 Chapter IV - PAKs in human cancer progression: from inception to cancer therapeutic to future oncobiology,
pp. 137–209 in Advances in Cancer Research, edited by Kenneth, D. T., and B. F. Paul. Academic Press, Cambridge, MA.

Lan, H., C. M. Kendzierski, J. D. Haag, L. A. Shepel, M. A. Newton et al., 2001 Genetic loci controlling breast cancer susceptibility in the Wistar-Kyoto rat. Genetics 157: 331–339.

Lesueur, F., P. D. Pharoah, S. Laing, S. Ahmed, C. Jordan et al., 2005 Allelic association of the human homologue of the mouse modifier Ptprij with breast cancer. Hum. Mol. Genet. 14: 2349–2356.

Madjl, Z., M. E. Akbari, A. H. Zarnani, M. Khayamzadeh, E. Kalantari et al., 2014 Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas. Asian Pac. J. Cancer Prev. 15: 1783–1789.

MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk, 2010 Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res. Treat. 119: 463–474.

Mavaddat, N., A. C. Antoniou, D. F. Easton, and M. Garcia-Closas, 2010 Genetic susceptibility to breast cancer. Mol. Oncol. 4: 174–191.

Moelans, C. B., R. A. de Weger, H. N. Monsuur, R. Vijzer, and P. J. van Moelans, C. B., R. A. de Weger, H. N. Monsuur, R. Vijzer, and P. J. van Diest, 2010 Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod. Pathol. 23: 1029–1039.

Pharoah, P. D., A. Antoniou, M. Bobrow, R. L. Zimmern, D. F. Easton et al., 2006 Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int. J. Cancer 125: 837–843.

Schaffer, B. S., C. M. Lachel, K. L. Pennington, C. R. Murrin, T. E. Strecker et al., 2006 Genetic bases of estrogen-induced tumorigenesis in the rat: mapping of loci controlling susceptibility to mammary cancer in a Brown Norway × A/J intercross. Cancer Res. 66: 7793–7800.

Shepel, L. A., H. Lan, J. D. Haag, G. M. Brasic, M. E. Gheen et al., 1998 Genetic identification of multiple loci that control breast cancer susceptibility in the rat. Genetics 149: 289–299.

Siegel, R. L., K. D. Miller, and A. Jemal, 2016 Cancer statistics, 2016. CA Cancer J. Clin. 66: 7–30.

Smith, P., L. McGuffog, D. F. Easton, G. J. Mann, G. M. Pupo et al., 2006 A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45: 646–655.

Srbacic, N., Z. Mugaric, J. Mijanovic-Mustedanagic, Z. Muminovic, and E. Cickus, 2011 Interleukin 18 expression in the primary breast cancer tumour tissue. Med Glas (Zenica) 8: 109–115.

Thomas, D. C., R. W. Haile, and D. Duggan, 2005 Recent developments in genomewide association scans: a workshop summary and review. Am. J. Hum. Genet. 77: 337–345.

Tsuda, H., S. Hirohashi, Y. Shimosato, T. Hirota, S. Tsugane et al., 1989 Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-co-amplification units: hst-1/int-2 and c-erbB-2/ker-1. Cancer Res. 49: 3104–3108.

Wang, R. A., H. Zhang, S. Balasenthil, D. Medina, and R. Kumar, 2005 PAK1 hyperactivation is sufficient for mammary gland tumor multiplicity. Am. J. Pathol. 166: 6299–6304.

Yang, H. J., Y. B. Zheng, T. Ji, X. F. Ding, C. Zhu et al., 2011 Physical confirmation and mapping of overlapping rat mammary carcinoma susceptibility QTLs, Mcs2 and Mcs6. PLoS One 6: e19891.

Yang, Y., S. Cheon, M. K. Jung, S. B. Song, D. Kim et al., 2015 Interleukin-18 enhances breast cancer cell migration via down-regulation of c-Met and induction of the p38 MAPK pathway. Biochem. Biophys. Res. Commun. 459: 379–386.

Communicating editor: D. W. Threadgill